{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:04:19Z","timestamp":1784631859584,"version":"3.55.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K09469"],"award-info":[{"award-number":["16K09469"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K08056"],"award-info":[{"award-number":["18K08056"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K08142"],"award-info":[{"award-number":["21K08142"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23591062"],"award-info":[{"award-number":["23591062"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26461088"],"award-info":[{"award-number":["26461088"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jjcc.2022.02.008","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T09:17:49Z","timestamp":1645780669000},"page":"26-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading?"],"prefix":"10.1016","volume":"81","author":[{"given":"Tsutomu","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2022.02.008_bib0001","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0006-291X(84)91077-5","article-title":"Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP)","volume":"118","author":"Kangawa","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0003","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/332078a0","article-title":"A new natriuretic peptide in porcine brain","volume":"332","author":"Sudoh","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0004","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/01.HYP.17.6.1152","article-title":"Expression of brain natriuretic peptide gene in human heart. Production in the ventricle","volume":"17","author":"Hosoda","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0005","doi-asserted-by":"crossref","first-page":"14730","DOI":"10.1073\/pnas.94.26.14730","article-title":"Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A","volume":"94","author":"Oliver","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0006","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1073\/pnas.070371497","article-title":"Cardiac fibrosis in mice lacking brain natriuretic peptide","volume":"97","author":"Tamura","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0007","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/01.CIR.0000029923.57048.61","article-title":"Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart","volume":"106","author":"Li","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0008","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0009","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1253\/circj.CJ-08-0130","article-title":"Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study","volume":"72","author":"Hata","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0010","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0011","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ejhf.799","article-title":"Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides","volume":"19","author":"D'Elia","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0012","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(12)60825-3","article-title":"New drugs, procedures, and devices for hypertension","volume":"380","author":"Laurent","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0013","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment","volume":"130","author":"Volpe","year":"2016","journal-title":"Clin Sci"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0014","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0015","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1253\/circj.CJ-17-1424","article-title":"Angiotensin receptor neprilysin inhibitor in Japanese patients with heart failure and reduced ejection fraction - baseline characteristics and treatment of PARALLEL-HF trial","volume":"82","author":"Tsutsui","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0016","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0017","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0018","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0019","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0020","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1253\/circj.CJ-21-0431","article-title":"JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0022","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycemic control in patients with heart failure and diabetes: a post hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0023","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0024","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsatan compared with enalapril: secondary analysis of the PARADIGM-HF Trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0025","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/eurheartj\/ehv015","article-title":"Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?","volume":"36","author":"Vodovar","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0026","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0027","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0028","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0029","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0030","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0031","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0032","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0033","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0034","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0035","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empaglifozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0036","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0037","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0038","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0039","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","article-title":"Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF","volume":"141","author":"Martinez","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0041","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jchf.2021.06.017","article-title":"Effects of dapagliflozin in patients with kidney disease, with and without heart failure","volume":"9","author":"McMurray","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0042","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/oxfordjournals.aje.a113046","article-title":"Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies","volume":"112","author":"Dyer","year":"1980","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0043","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/0002-8703(87)90666-1","article-title":"Heart rate and cardiovascular mortality: the Framingham study","volume":"113","author":"Kannel","year":"1987","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0044","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/0002-8703(93)90128-V","article-title":"Influence of heart rate on mortality among persons with hypertension: the Framingham study","volume":"125","author":"Gillman","year":"1993","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0045","first-page":"1104","article-title":"Rest heart rate and life expectancy","volume":"30","author":"Levine","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0046","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.amjcard.2007.11.023","article-title":"Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers","volume":"101","author":"Flannery","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0047","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/01.CIR.103.10.1428","article-title":"Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial","volume":"103","author":"Luchat","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0048","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijcard.2012.11.051","article-title":"Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: japanese chronic heart failure (J-CHF) study","volume":"164","author":"Okamoto","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0049","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2011.12.044","article-title":"Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program","volume":"59","author":"Castagno","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0050","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ejhf.22","article-title":"Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 study","author":"Takada","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0051","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ejhf.85","article-title":"Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)","volume":"16","author":"B\u00f6hm","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0052","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.jacc.2017.08.022","article-title":"Heart rate and outcomes in hospitalized patients with heart failure with preserved ejection fraction","volume":"70","author":"Lam","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0053","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/oxfordjournals.eurheartj.a060471","article-title":"Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy","volume":"15","author":"Hasenfuss","year":"1994","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0054","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1172\/JCI114611","article-title":"Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium","volume":"85","author":"Gwathmey","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0055","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0056","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"B\u00f6hm","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0057","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","article-title":"Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0058","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2011.11.082","article-title":"Endothelial dysfunction, arterial stiffness, heart failure","volume":"60","author":"Marti","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0059","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0060","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0061","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0062","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the Soluble guanylate Cyclase stimulatoR in heart failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0063","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0064","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1126\/science.1200113","article-title":"Cardiac myosin activation: a potential therapeutic approach for systolic heart failure","volume":"331","author":"Malik","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0065","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial","volume":"388","author":"Teerlink","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0066","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0067","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomized controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2022.02.008_bib0068","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508722000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508722000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:07:38Z","timestamp":1760274458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508722000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0914508722000314"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.02.008","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading?","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}